Targeted toxin active in platinum-resistant ovarian cancers
A new antibody-guided drug has shown promising activity in a phase I trial involving ovarian cancer patients with platinum drug-resistant disease, researchers from Dana-Farber Cancer Institute will report today at the annual ...
Apr 6, 2013